A phase II dose-ranging study of mirabegron in patients with overactive bladder

Overview of attention for article published in International Urogynecology Journal & Pelvic Floor Dysfunction, March 2013

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (86th percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

So far, Altmetric has seen 1 X post from an account with 2,303 followers.

Waiting for Mirabegron to get TGA approval in Australia, and waiting, and waiting. http://t.co/mOWL1zsZIU